Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients with Alcohol Dependence

Mark A Frye, David J. Hinton, Victor M Karpyak, Joanna M Biernacka, Lee J. Gunderson, Scott E. Feeder, Doo Sup Choi, John D Port

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although the precise drug mechanism of action of acamprosate remains unclear, its antidipsotropic effect is mediated in part through glutamatergic neurotransmission. We evaluated the effect of 4 weeks of acamprosate treatment in a cohort of 13 subjects with alcohol dependence (confirmed by a structured interview, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) on proton magnetic resonance spectroscopy glutamate levels in the midline anterior cingulate cortex (MACC). We compared levels of metabolites with a group of 16 healthy controls. The Pennsylvania Alcohol Craving Scale was used to assess craving intensity. At baseline, before treatment, the mean cerebrospinal fluid-corrected MACC glutamate (Glu) level was significantly elevated in subjects with alcohol dependence compared with controls (P = 0.004). Four weeks of acamprosate treatment reduced glutamate levels (P = 0.025), an effect that was not observed in subjects who did not take acamprosate. At baseline, there was a significant positive correlation between cravings, measured by the Pennsylvania Alcohol Craving Scale, and MACC (Glu) levels (P = 0.019). Overall, these data would suggest a normalizing effect of acamprosate on a hyperglutamatergic state observed in recently withdrawn patients with alcohol dependence and a positive association between MACC glutamate levels and craving intensity in early abstinence. Further research is needed to evaluate the use of these findings for clinical practice, including monitoring of craving intensity and individualized selection of treatment with antidipsotropic medications in subjects with alcohol dependence.

Original languageEnglish (US)
Pages (from-to)669-674
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume36
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Gyrus Cinguli
Alcoholism
Glutamic Acid
Therapeutics
Alcohols
Synaptic Transmission
Diagnostic and Statistical Manual of Mental Disorders
Cerebrospinal Fluid
acamprosate
Craving
Interviews
Research
Pharmaceutical Preparations

Keywords

  • acamprosate
  • alcohol dependence
  • craving
  • glutamate
  • MACC
  • MRS

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients with Alcohol Dependence. / Frye, Mark A; Hinton, David J.; Karpyak, Victor M; Biernacka, Joanna M; Gunderson, Lee J.; Feeder, Scott E.; Choi, Doo Sup; Port, John D.

In: Journal of Clinical Psychopharmacology, Vol. 36, No. 6, 01.12.2016, p. 669-674.

Research output: Contribution to journalArticle

@article{edbe866d71414e8cb1b0a730efa8bd6f,
title = "Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients with Alcohol Dependence",
abstract = "Although the precise drug mechanism of action of acamprosate remains unclear, its antidipsotropic effect is mediated in part through glutamatergic neurotransmission. We evaluated the effect of 4 weeks of acamprosate treatment in a cohort of 13 subjects with alcohol dependence (confirmed by a structured interview, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) on proton magnetic resonance spectroscopy glutamate levels in the midline anterior cingulate cortex (MACC). We compared levels of metabolites with a group of 16 healthy controls. The Pennsylvania Alcohol Craving Scale was used to assess craving intensity. At baseline, before treatment, the mean cerebrospinal fluid-corrected MACC glutamate (Glu) level was significantly elevated in subjects with alcohol dependence compared with controls (P = 0.004). Four weeks of acamprosate treatment reduced glutamate levels (P = 0.025), an effect that was not observed in subjects who did not take acamprosate. At baseline, there was a significant positive correlation between cravings, measured by the Pennsylvania Alcohol Craving Scale, and MACC (Glu) levels (P = 0.019). Overall, these data would suggest a normalizing effect of acamprosate on a hyperglutamatergic state observed in recently withdrawn patients with alcohol dependence and a positive association between MACC glutamate levels and craving intensity in early abstinence. Further research is needed to evaluate the use of these findings for clinical practice, including monitoring of craving intensity and individualized selection of treatment with antidipsotropic medications in subjects with alcohol dependence.",
keywords = "acamprosate, alcohol dependence, craving, glutamate, MACC, MRS",
author = "Frye, {Mark A} and Hinton, {David J.} and Karpyak, {Victor M} and Biernacka, {Joanna M} and Gunderson, {Lee J.} and Feeder, {Scott E.} and Choi, {Doo Sup} and Port, {John D}",
year = "2016",
month = "12",
day = "1",
doi = "10.1097/JCP.0000000000000590",
language = "English (US)",
volume = "36",
pages = "669--674",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients with Alcohol Dependence

AU - Frye, Mark A

AU - Hinton, David J.

AU - Karpyak, Victor M

AU - Biernacka, Joanna M

AU - Gunderson, Lee J.

AU - Feeder, Scott E.

AU - Choi, Doo Sup

AU - Port, John D

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Although the precise drug mechanism of action of acamprosate remains unclear, its antidipsotropic effect is mediated in part through glutamatergic neurotransmission. We evaluated the effect of 4 weeks of acamprosate treatment in a cohort of 13 subjects with alcohol dependence (confirmed by a structured interview, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) on proton magnetic resonance spectroscopy glutamate levels in the midline anterior cingulate cortex (MACC). We compared levels of metabolites with a group of 16 healthy controls. The Pennsylvania Alcohol Craving Scale was used to assess craving intensity. At baseline, before treatment, the mean cerebrospinal fluid-corrected MACC glutamate (Glu) level was significantly elevated in subjects with alcohol dependence compared with controls (P = 0.004). Four weeks of acamprosate treatment reduced glutamate levels (P = 0.025), an effect that was not observed in subjects who did not take acamprosate. At baseline, there was a significant positive correlation between cravings, measured by the Pennsylvania Alcohol Craving Scale, and MACC (Glu) levels (P = 0.019). Overall, these data would suggest a normalizing effect of acamprosate on a hyperglutamatergic state observed in recently withdrawn patients with alcohol dependence and a positive association between MACC glutamate levels and craving intensity in early abstinence. Further research is needed to evaluate the use of these findings for clinical practice, including monitoring of craving intensity and individualized selection of treatment with antidipsotropic medications in subjects with alcohol dependence.

AB - Although the precise drug mechanism of action of acamprosate remains unclear, its antidipsotropic effect is mediated in part through glutamatergic neurotransmission. We evaluated the effect of 4 weeks of acamprosate treatment in a cohort of 13 subjects with alcohol dependence (confirmed by a structured interview, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) on proton magnetic resonance spectroscopy glutamate levels in the midline anterior cingulate cortex (MACC). We compared levels of metabolites with a group of 16 healthy controls. The Pennsylvania Alcohol Craving Scale was used to assess craving intensity. At baseline, before treatment, the mean cerebrospinal fluid-corrected MACC glutamate (Glu) level was significantly elevated in subjects with alcohol dependence compared with controls (P = 0.004). Four weeks of acamprosate treatment reduced glutamate levels (P = 0.025), an effect that was not observed in subjects who did not take acamprosate. At baseline, there was a significant positive correlation between cravings, measured by the Pennsylvania Alcohol Craving Scale, and MACC (Glu) levels (P = 0.019). Overall, these data would suggest a normalizing effect of acamprosate on a hyperglutamatergic state observed in recently withdrawn patients with alcohol dependence and a positive association between MACC glutamate levels and craving intensity in early abstinence. Further research is needed to evaluate the use of these findings for clinical practice, including monitoring of craving intensity and individualized selection of treatment with antidipsotropic medications in subjects with alcohol dependence.

KW - acamprosate

KW - alcohol dependence

KW - craving

KW - glutamate

KW - MACC

KW - MRS

UR - http://www.scopus.com/inward/record.url?scp=84991512374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991512374&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000590

DO - 10.1097/JCP.0000000000000590

M3 - Article

C2 - 27755217

AN - SCOPUS:84991512374

VL - 36

SP - 669

EP - 674

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -